# Biointron

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biointron

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.biointron.com
- Total disclosed funding: $88M
- Latest round: Series B (Aug 31, 2022)
- Investors on record: 13

## About

Based in Jiangsu, China and established in 2012, Biointron operates as a contract research organization (CRO) vendor that engages in recombinant antibody drug R&D and related outsourcing services. The company has R&D and production center located in Jiangsu and business center located in the USA and Netherlands. It has more than 400 employees and over 14,600 square meter production area.

The company provides recombinant protein and antibody reagents for biotech and biopharma companies. The company develops high throughput recombinant antibody expression platform, phage library antibody development platform and single cell antibody development platform. It adopts microfluidic sorting and identification technologies. The business of the company includes antibody discovery, antibody production, stable cell line and protein expression. Antibody discovery include VHH library generation, single B cell screening, hybridoma sequencing, antibody humanization and affinity maturation.

## Funding rounds

- Series B, Aug 31, 2022, $73M — CoStone Capital, Gaorong Ventures, CS Capital, Furong Capital, Befor Capital, Shiyue Capital, JSVC, ALAN AMC, Guangzhou Tianhui Capital Management, Jifeng Ventures, Haitong Innovation Securities Investment, Xishanghai Motor Services Co.,Ltd.
- Series A, Jul 28, 2021 — CS Capital
- Series A, May 22, 2021, $16M — Furong Capital, Tigermed

## Investors

- Furong Capital (https://capitalatlas.ai/funds/furong-capital) — Series A, Series B
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series A
- CS Capital — Series A, Series B
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series B
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series B
- Befor Capital (https://capitalatlas.ai/funds/befor-capital) — Series B
- Shiyue Capital — Series B
- JSVC — Series B
- ALAN AMC (https://capitalatlas.ai/funds/alan-amc) — Series B
- Guangzhou Tianhui Capital Management — Series B
- Jifeng Ventures (https://capitalatlas.ai/funds/jifeng-ventures) — Series B
- Haitong Innovation Securities Investment — Series B
- Xishanghai Motor Services Co.,Ltd. — Series B